Monoclonal antibodies in treatment of myasthenia gravis

Myasthenia gravis (MG) is an anti-acetylcholine receptor antibody mainly mediated, T cellular dependent and multiple complement involved acquired autoimmune disease. Anticholinesterase drug (pyridostigmine bromide), corticosteroid and azathioprine are usually used as first-line therapy due to their demonstrated effect in patients with diagnosed MG. Nevertheless, some patients with refractory MG cannot benefit from conventional treatment, and long-term application of agents may lead to obvious side effects. Recently, the emerging monoclonal antibodies with higher safety and specific targets may provide new treatment options for MG. This review discussed the currently latest research progress in this field. Key words: Myasthenia gravis; Autoimmunity; Monoclonal antibody; Immunotherapy